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The addition of ribavirin (RBV) to interferon-based therapy
against hepatitis C virus (HCV) has been a therapeutic break-
through. All therapies against HCV are based on a combination
of pegylated interferon and RBV. The mechanism(s) of action of
RBV remain partly unknown. The ﬁrst attempts at triple drug
therapies with protease inhibitors plus interferon showed that
addition of RBV remains an essential element to achieve sus-
tained virologic response (SVR). However, intake of RBV is associ-
ated with a severe dose-dependant haemolytic anaemia limiting
the tolerance and the efﬁcacy of treatment. Viramidin (VRD) is a
prodrug of RBV and is metabolized primarily in the liver to RBV
without accumulation of VRD in red blood cells thus reducing
the degree of anaemia with an expected similar antiviral effect.
In a phase III study described by Marcellin et al., a combination
of VRD 600 mg bid plus Peginterferon alpha 2a was compared
to a standard dosing regimen of RBV plus Peginterferon alpha
2a. Overall, SVR was higher in the RBV group (54%) vs. the VRD
(40%) group and the non-inferiority point, a main objective of
the study, was not reached. This trend of lower SVR in the VRD
group was conﬁrmed in genotypes 1 and 2/3 HCV patients. As
expected, there was signiﬁcantly less decrease in haemoglobin
(54%) in the VRD group than in the RBV group (80%) p < 0.001.
The lower efﬁcacy of VRD in comparison to RBV still remains a
debateable issue. The authors suggest that the optimal dosages
of VRD still remains to be established; therefore, further studies
are required to test the hypothesis that different dosages of
VRD will provide a better safety proﬁle with a similar efﬁcacy
as compared to RBV.Duration of therapy in HCV genotype 1 with rapid virologic
response
The standard of care for HCV infected genotype 1 patients is the
combination of Peginterferon recombinant alpha plus ribavirin
for a duration of 48 weeks. There is a debate on the duration of
therapy in those patients who achieve a rapid decline in viral load
(>2 log drop at week 4) or a complete suppression of viral load
(i.e. HCV RNA <50 IU/ml) at week 4. Some reports have suggested
that in these patients a shorter treatment duration of 24 weeks
would achieve a similar SVR with improved tolerance at a lower
cost. However, higher relapse rates have also been reported inJournal of Hepatology 20
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als, Moreno et al., in this issue looked at the impact of shorter
treatment duration on the SVR rate in HCV genotype 1 patients.
Overall the SVR rate was lower in the short duration treatment
groups due to a higher virologic relapse rate. In the subgroup of
patients with RVR at week 4 and with a HCV RNA pre-treatment
level below 400.000 IU/ml, the SVR rate was similar in both
groups. Thus, the advantage of a shorter duration of therapy in
genotype 1 patients seems limited to a small group of patients
with rapid virological response and low viral load.Targeted therapies in hepatocellular carcinoma
Sorafenib has recently been licensed for treatment of unresec-
table hepatocellular carcinoma (HCC). Sorafenib targets Raf, Vas-
cular endothelium growth factor receptor 1, 2, and 3 (VEGF-Rs)
and platelet derived growth factor receptor (PDGF-Rb). Sorafenib
has been shown to improve survival in comparison to conven-
tional treatment in patients with advanced unresectable HCC.
The exact mode of action of Sorafenib is still unknown; however,
its main action is believed to be through inhibition of VEGF-R.
Despite the important therapeutic advance provided by Sorafe-
nib, there is still a long way to go in control of HCC. Two studies
in this issue of the Journal have explored the potential of
enhanced activity of Sorafenib in combination therapy with other
drugs. Chen et al. looked at the mechanism of the synergistic
interactions between Sorafenib and bortezomib. Bortezomib is a
proteasome inhibitor approved for the treatment of multiple
myeloma. HCC cells in culture such as PLC-5 are highly resistant
to bortezomib-induced apoptosis due to the inability of bortezo-
mib to down regulate phospho-Akt in these cells. The investiga-
tors showed that pre-treatment with Sorafenib overcomes
resistance to bortezomib in PLC-5 HCC cells and this effect is
mediated through protein-phosphatase 2A (PP2A)-Akt inactiva-
tion. The Raf/MEK/ERK pathway is an important pathway in liver
tumorigenesis. Huynh et al. showed that the inhibition of MEK/
ERK pathway by AZD 6244 enhanced the antitumor effect of
Sorafenib in a mice model of HCC. This paper suggests that a com-
bination of angiogenesis inhibitors and the ERK/MEK pathway are
effective to suppress tumour growth in a xenograft model of HCC
by suppressing the feedback activation pathway of ERK/MEK.
Thus, the anti-tumoral effect of the combination of Sorafenib/
AZ 6244 was more effective than Sorafenib monotherapy in this
model. In a third paper, Aihara et al. described the effect of
AZD1152, an Aurora B kinase inhibitor on HCC growth. The
Aurora kinase family of serine–threonine kinases controls chro-10 vol. 52 j 3–4
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mosome assembly and segregation during mitosis. Aberrant
expression of the Aurora kinases has been reported in several
solid tumours. The effect of AZD1152 has been tested in human
HCC cell lines and in a heterotopic and orthotopic xenograft
mouse model. In these models, AZD1152 decreases tumour vol-4 Journal of Hepatology 2ume and improves survival of treated mice. Thus, the fundamen-
tal research in controlling HCC pathways is expected to open the
ﬁeld for new therapies against HCC; however, these experimental
results require conﬁrmation in human HCC patients.010 vol. 52 j 3–4
